Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent

BRIDGEWATER, N.J.--(HSMN NewsFeed)--Cordis Corporation, a worldwide leader in the field of interventional cardiology, announced plans today to launch a global, head-to-head, randomized clinical trial called NEVO II which will compare the NEVO(TM) Sirolimus-eluting Coronary Stent to the XIENCE V(TM) Everolimus-eluting Coronary Stent. Cordis Corporation and Conor Medsystems, LLC are sponsors of the study. NEVO(TM) is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology, which Cordis acquired from Conor Medsystems, LLC in 2007, and incorporates hundreds of small reservoirs, each acting as a depot into which drug-polymer compositions are loaded. This revolutionary design allows drug delivery from a stent with a surface that is 75 percent bare metal upon insertion and becomes fully bare metal following drug delivery and polymer bioresorption in approximately three months.

Full text >>